Life Sciences Real Estate #18

✅ Germany: TRON grows at Mainz ✅ Ireland: new lease in Cork ✅ Spain: Barcelona and Zaragoza ✅ UK: Liverpool and London calling
17 Columbus Yard in London's Canary Wharf
17 Columbus Yard in London's Canary Wharf
17 Columbus Yard in London's Canary Wharf
17 Columbus Yard in London's Canary Wharf

Welcome subscribers,

In this edition, we examine the world of pharmaceutical distribution and the appeal it has for real estate investors. We also report on new assets, extended assets, sales, and leasing activity from many parts of Europe, so please enjoy!

Germany: TRON grows at Mainz
Ireland: new lease in Cork
Spain: Barcelona and Zaragoza
UK: Liverpool and London calling

Read more below for all the details.

From lab to jab

The real estate backbone of pharmaceutical distribution

Read the full article

Was this email forwarded to you? Did you know that you can subscribe to Life Sciences Real Estate and get access to all our resources?

New and extended assets

TRON in Mainz
TRON in Mainz

Sandoz inaugurated a new antibiotic production plant in Kundl in November 2023. Sandoz has the only major remaining vertically-integrated production network for penicillin in Europe. The €150 million (£128 million) investment, which includes a contribution of €50 million (£43 million) from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.


A groundbreaking ceremony took place on the premises of the University Medical Center Mainz, where TRON-Mainz is planning and constructing a new research and administration building. The six-storey building with approximately 10,000 sq m (108,000 sq ft) of usable space will be completed in 2027. TRON is an institute for translational research whose co-founders include Professor Ugur Sahin and Dr. Özlem Türeci who spearheaded the Pfizer/BioNTech COVID vaccine.


Demand for ceramic components for joint replacement is growing. CeramTec, the advanced ceramics specialist, has reacted by expanding its manufacturing capacities in Marktredwitz, Upper Franconia. The first construction phase of the new building covers a total area of around 11,000 sq m (118,000 sq ft), and there is potential for further expansion on the site. The company plans to complete and fully commission the building by 2026.


Catalent is working on a €19 million (£16 million) expansion at its clinical supply facility in Schorndorf, Baden-Württemberg. The new facility adds capacity for the storage and handling of clinical trial supply materials at controlled room temperatures of between 15 and 25 degrees Celsius. The project will see the site’s footprint increase by 2,970 sq m (32,000 sq ft) and it will create space in the original building to accommodate the installation of a new, fully automatic bottle-filling line. Work is expected to be completed by June 2024.


The Aenova Group, a contract manufacturer and development service provider for the pharmaceutical and healthcare industry, is installing new packaging and bulk production capacity. The total investment is around €35 million (£30 million) and the goal is to increase capacity by two to three billion packaged tablets in the final expansion stage. The Tittmoning site already produces around 10 billion tablets and capsules per year. A total of four high-speed packaging lines will go into operation by the first quarter of 2025. A new line for large volume bulk products will be ready by the end of 2024.


Maghull Health Park, a 404,686 sq m (100-acre) NHS site located off Junction One of the M58, is set to undergo a significant expansion as part of Liverpool City Region's life sciences investment zone. Mersey Care NHS Foundation Trust is leading the project, with ION Developments appointed as the development manager for the £25 million (€29 million) Maghull Health Park expansion.


ISG is in line to win the £65 million (€76 million) contract to convert a London Docklands office block into a life-sciences facility. The contractor has been working on designs for the scheme under a preconstruction agreement it won last year. The 17 Columbus Courtyard project, designed by architect Scott Brownrigg, is set to become the UK’s second-biggest office-to-life-sciences repurposing scheme.


Reef Group has appointed Ardmore, the construction company, to deliver the final phase of TRIBECA, London’s largest purpose-built life science campus, in the King’s Cross Knowledge Quarter. Three new buildings named The Reflector, The Assembly and The Connector will offer lab spaces for life science businesses. The Apex, the first laboratory building on the TRIBECA campus, has secured the London BioScience Innovation Centre (LBIC) as its first tenant.


Plans were announced for a new Oxford life science redevelopment, transforming three buildings into a new five-storey facility called Bridge Labs. Forge Bio GP 2 has submitted a proposal to Oxford City Council to transform the city centre buildings to provide flexible labs and offices along with public amenities. Bridge Labs also has facilities in Cambridge and Stevenage.


Scott Brownrigg’s £35 million (€41 million) masterplan for Wootton Science Park was unveiled in March. The masterplan includes circa 106,233 sq ft (9,869 sq m) of new commercial laboratory space across five buildings, including greenspace, secure bike storage, restaurant and gym facilities. 


This section is for paying members only.

Stay on top of the life sciences real estate markets in Europe

Join us
Great! You’ve successfully signed up.
Welcome back! You've successfully signed in.
You've successfully subscribed to Life Sciences Real Estate.
Your link has expired.
Success! Check your email for magic link to sign-in.
Success! Your billing info has been updated.
Your billing was not updated.